H.R.4769 - Medicare Prescription Drug Savings and Choice Act of 2019116th Congress (2019-2020) |
|Sponsor:||Rep. Schakowsky, Janice D. [D-IL-9] (Introduced 10/21/2019)|
|Committees:||House - Energy and Commerce; Ways and Means|
|Latest Action:||House - 10/21/2019 Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (All Actions)|
This bill has the status Introduced
Here are the steps for Status of Legislation:
- Passed House
- Passed Senate
- To President
- Became Law
Summary: H.R.4769 — 116th Congress (2019-2020)All Information (Except Text)
Introduced in House (10/21/2019)
Medicare Prescription Drug Savings and Choice Act of 2019
This bill requires the Centers for Medicare & Medicaid Services (CMS) to establish at least one prescription drug plan that is operated by Medicare.
Among other things, the plan must (1) serve the entire United States; and (2) be the default plan for enrollees under the Medicare prescription drug benefit, unless the enrollee chooses another plan.
Additionally, the CMS must negotiate prices for prescription drugs that are covered under the plan and, if appropriate, encourage the use of more affordable therapeutic equivalents. (Currently, the CMS is prohibited from negotiating the prices of covered drugs under the Medicare prescription drug benefit.) The Agency for Healthcare Research and Quality must assess the clinical benefits of drugs and make recommendations to the CMS regarding price negotiations, based on specified information (e.g., comparable international prices).